Table 8. Survival according to definition of inactive carrier based on FibroTest-ActiTest normal values in untreated patients.

Baseline definition of inactive carrier	N	HBV complications	Survival without HBVcomplications	HBV Related Death	Survival without HBV death	Death	Overall Survival	Overall Survival in paired controls
All untreated patient	428	8	97.4 (95.5–99.2)	6	98.2 (96.8–99.7)	8	97.4 (95.5–99.2)	99.2 (99.0–99.5)
Normal FibroTest and ActiTest *	303	0	100**	0	100**	0	100**	99.6 (99.5–99.6)
Abnormal FibroTest or ActiTest ***	125	8	90.8 (84.5–97.1)	6	93.7 (88.8–98.7)	8	90.8 (84.5–97.1)	98.5 (97.8–99.2)
Without HIV, HCV, Delta	397	6	97.7 (95.8–99.6)	4	98.7 (97.3–99.9)	6	97.7 (95.8–99.6)	99.2 (99.0–99.5)
Normal FibroTest and ActiTest	289	0	100	0	100	0	100	99.6 (99.5–99.6)
Abnormal FibroTest or ActiTest	108	6	91.2 (84.2–98.1)	4	94.7 (89.7–99.8)	6	91.2 (84.2–98.1)	98.4 (97.6–99.1)
With HIV, HCV, Delta ***	31	2	92.8 (83.2–100)	2	92.8 (83.2–100)	2	92.8 (83.2–100)	99.4 (99.2–99.6)
Normal FibroTest and ActiTest	14	0	100	0	100	0	100	99.5 (99.2–99.7)
Abnormal FibroTest or ActiTest	17	2	87.5 (71.3–100)	2	87.5 (71.3–100)	2	87.5 (71.3–100)	99.3 (99.0–99.7)
Classical Inactive carrier $
Yes	275	3	98.1 (95.9–100)	1	99.5 (98.5–100)	3	98.1 (95.9–100)	99.1 (98.8–99.4)
No	153	5	95.9 (92.4–99.5)	5	95.9 (92.4–99.5)	5	95.9 (92.4–99.5)	99.4 (99.2–99.7)

^*Both normal values: FibroTest < = 0.27 and ActiTest < = 0.29.

^**Survivals of patients with abnormal FibroTest and ActiTest were lower than those of normal FibroTest and ActiTest (p<0.005).

^***Survivals of patients with or without one coinfection (HVI, HCV, Delta) were not significantly different (p>0.05).

^****Overall survivals of patients with abnormal FibroTest and ActiTest were lower to those in paired controls (p<0.005).

^$Inactive carrier: anti HBe, normal ALT, viral load <2,000 IU/ml, no coinfection HCV, HIV, or Delta.